41st week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150283224 | INFLUENZA VACCINES - The invention relates to a method for the treatment or prevention of an influenza virus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a gamma-irradiated influenza virus. | 2015-10-08 |
20150283225 | RECOMBINANT HVT VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF - The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. | 2015-10-08 |
20150283226 | COMPOSITIONS AND METHODS OF MODULATING AN IMMUNE RESPONSE - Compositions for and methods of stimulating a MHC I mediated immune response comprising stimulating MHC I endolysosomal cross presentation in dendritic cells. Stimulation MHC I endolysosomal cross presentation may comprise over-expression CD74 in dendritic cells and/or targeting antigens to the MHC I endolysosomal cross presentation pathway. Fusion proteins comprising an antigen or fragment thereof and a CD74 endolysosomal targeting sequence are also provided. | 2015-10-08 |
20150283227 | SYNTHETIC ENV PROTEINS - The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1), and, in particular to a vaccine for HIV-1 and to methods of making and using same. The present invention provides synthetic glycosylated HIV-1 peptides, method for their preparation and use. | 2015-10-08 |
20150283228 | Recombinant Feline Leukemia Virus Vaccine Containing Optimized Feline Leukemia Virus Envelope Gene - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 2015-10-08 |
20150283229 | PORCINE EPIDEMIC DIARRHEA VIRUS VACCINE - The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided. | 2015-10-08 |
20150283230 | PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 2015-10-08 |
20150283231 | Induction of Antigen-Specific Tolerance by Peripheral Phagocytosis - The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation. | 2015-10-08 |
20150283232 | IMMUNOGENIC COMPOSITIONS - The invention provides an immunogenic composition comprising: (a) a conjugate that is a capsular saccharide from GBS serotype I1 conjugated to a carrier protein; (b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; and (c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunizing a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunized with a diphtheria toxoid or derivative thereof. | 2015-10-08 |
20150283233 | Compositions and Methods for Enhancing Immune Responses - Compositions and methods for inducing, enhancing, or promoting an immune response are disclosed. In some embodiments the increased immune response is against an antigen such as a tumor antigen or a viral antigen. Immune responses include activation of cytotoxic T cells to kill cells displaying the antigen. In some embodiments, the methods include contacting cells with an effective amount of a transcription factor A-mitochondrial (TFAM) fusion protein to increase expression of a Major Histocompatibility Complex I (MHC I), reduce expression of HLA-G on the surface of cells, or increase expression of one or more cytokines or chemokines Methods of treating cancer are also disclosed. | 2015-10-08 |
20150283234 | COMBINATION OF ANTI-KIR AND ANTI-CTLA-4 ANTIBODIES TO TREAT CANCER - Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody. | 2015-10-08 |
20150283235 | IMMUNE-TOLERANCE INDUCER - The purpose of the present invention is to create an immune tolerance-inducing agent used in therapy in which donor hematopoietic cells are transplanted into a recipient in order to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. By using an alpha-galactosylceramide-containing liposome in combination with a costimulatory-pathway-blocking substance, hematopoietic chimerism can be induced in the recipient by transplantation of donor hematopoietic cells, making it possible to induce immune tolerance in the recipient with respect to donor cells, tissue, or organs. | 2015-10-08 |
20150283236 | METHODS FOR TREATING SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED - The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P. The methods of the present invention are useful for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy. | 2015-10-08 |
20150283237 | CTLA-4 BLOCKADE WITH METRONOMIC CHEMOTHERAPY FOR THE TREATMENT OF CANCER - The present invention is directed to methods for treating cancer by administering an anti-CTLA-4 agent in combination with a metronomic chemotherapy or a sequential chemotherapy. | 2015-10-08 |
20150283238 | Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2 - The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions. | 2015-10-08 |
20150283239 | GRAPHENE DERIVATIVE-BASED COMPOSITION FOR DRUG DELIVERY AND PREPARATION METHOD THEREOF - A graphene derivative-based composition for drug delivery, a method of preparing the graphene derivative-based composition, and a method of drug delivery using a graphene derivative-based carrier are provided. The graphene derivative-based composition for drug delivery includes a nanocomposite including a drug loaded on a carrier. | 2015-10-08 |
20150283240 | STABILIZED COMPOSITIONS COMPRISING A THERAPEUTICALLY ACTIVE AGENT AND AN OXIDIZING PRESERVATIVE - Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein. | 2015-10-08 |
20150283241 | STABLE PHARMACEUTICAL COMPOSITION OF TNFR:FC FUSION PROTEIN - The present invention relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). More particularly, it relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc), phosphate-citrate buffer. It also relates to the methods of manufacturing the composition, method of administration and kits containing the same. | 2015-10-08 |
20150283242 | EFFECTIVE PHARMACEUTICAL CARRIER FOR POORLY BIOAVAILABLE DRUGS - The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from 2 to 4 (having poor solubility in both water and triglycerides) as well as those with high log P of more than 4. | 2015-10-08 |
20150283243 | SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF - The present invention relates to a solid dispersion characterized in that it comprises carbamic acid 3-(4-ben-zyloxy-phenyl)-isoxazol-5-ylmethyl ester as an active ingredient and a water-soluble polymer having a glass transition temperature lower than the melting point of the active ingredient as a carrier, and it is prepared via melt extrusion. The solid dispersion of the present invention remarkably increases the solubility and dissolution rate of the active ingredient which is an insoluble drug to efficiently improve the bioavailability when it is orally administered. | 2015-10-08 |
20150283244 | SEMI-SOLID DELIVERY SYSTEMS - The invention provides semi-solid systems for delivering biologically active materials that include a polymer comprising 1) one or more units of formula Ia, IIa, or IIIa: (formula Ia, IIa, IIIa) and 2) one or more units comprising polycaprolactone; wherein R and R | 2015-10-08 |
20150283245 | STABILIZER FOR HYALURONIDASE AND LIQUID FORMULATION COMPRISING HYALURONIDASE - This invention relates to a stable liquid formulation comprising hyaluronidase and a stabilizer for hyaluronidase and more particularly, to a stable liquid formulation by the addition of the stabilizer to the hyaluronidase. | 2015-10-08 |
20150283246 | Amphiphilic Block Copolymer And Preparation Method Thereof And Micellar Drug-Loading System Formed By Same With Antitumor Drug - The present invention relates to a novel amphiphilic block copolymer and the preparation method thereof, as well as a micellar drug-loaded system formed by said copolymer and an anti-tumor drug. Said amphiphilic block copolymer comprises a hydrophilic segment and a hydrophobic segment, and the end group of said hydrophobic segment is end-capped with a hydrophobic group. Methoxypolyethylene glycol (or polyethylene glycol)-polyester block copolymer which has recognized safety is used as a fundamental material of the amphiphilic block copolymer of the present invention, and the terminal hydroxyl group of the polyester segment is modified with a hydrophobic group, whereby the compatibility between the drug molecule and the hydrophobic segments of the block copolymer is improved, and the interaction therebetween is enhanced. Moreover, a larger space for accommodating the drug molecules is provided. Said micelles are more effective in restricting the drug molecules inside the micellar core and preventing the drug from dissolved out of the micelles. Therefore, a drug-loaded micelle with high stability is obtained. | 2015-10-08 |
20150283247 | GLUCOSE RESPONSIVE HYDROGEL COMPRISING PBA-GRAFTED HYALURONIC ACID (HA) - Polymer composition comprising a mixture of PBA modified HA polymer grafted on at least a hydroxyl with a group comprising phenylboronic acid and Cis-diol modified HA polymer grafted on at least a hydroxyl with a group comprising a cis-diol. Injectable or implantable glucose-sensitive hydrogels comprising a this polymer composition. | 2015-10-08 |
20150283248 | Pharmaceutical compositions of Linagliptin and process for preparation thereof - Pharmaceutical compositions comprising an antidiabetic agent as an active agent are provided. The present invention relates to pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof as an active agent. The present invention also relates to process of preparation of pharmaceutical compositions comprising linagliptin or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising linagliptin to a subject in need thereof. | 2015-10-08 |
20150283249 | AMORPHOUS FORM OF APREMILAST - The present invention provides an amorphous form of apremilast and process for preparation thereof. The present invention also provides a pharmaceutical composition comprising an amorphous apremilast and one or more of pharmaceutically acceptable carriers, excipients or diluents used for the treatment of active psoriatic arthritis. | 2015-10-08 |
20150283250 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-08 |
20150283251 | CATECHIN BIOAVAILABILITY ENHANCER COMPRISING CYCLODEXTRIN - Disclosed is a catechin bioavailability enhancer comprising cyclodextrin as an active ingredient. Further, disclosed is a composition comprising a catechin bioavailability enhancer comprising catechin and cyclodextrin. The composition disclosed in the present specification may improve the stability of catechin which has significantly low intestinal absorption rate, and thus may improve bioaccessibility, intestinal transport rate and bioavailability of catechin. Accordingly, the improved bioavailability may further increase the effects of catechin such as the effects of reducing weight and body fat, anti-oxidative effects and anti-aging effects. The composition disclosed in the present specification having the abovementioned characteristics can be effectively used in the fields of food or pharmacy. | 2015-10-08 |
20150283252 | STABLE PHARMACEUTICAL COMPOSITION OF PEGINTERFERON ALPHA-2B - The present invention relates to the stable pharmaceutical compositions comprising PEG-interferon alpha-2b. More particularly, it relates to the stable pharmaceutical compositions comprising PEG-interferon alpha-2b and cryoprotectant selected from the group consisting of 2-Hydroxy propyl beta-cyclodextrin, sucralose, or polyvinylpyrrolidone 4000. It also relates to the methods of manufacturing the composition, method of administration and kits containing the same. | 2015-10-08 |
20150283253 | NOVEL POLYMER-BASED HYDROTROPES FOR HYDROPHOBIC DRUG DELIVERY - Polymer conjugates characterized in that the backbone of the polymer is an anionic polymer and hydrophobic moieties are covalently attached to the polymer backbone are useful for preparing drug encapsulated polymer hydrotropes and compositions. Such materials are useful in methods for delivering the drug into cells, and for the treatment and alleviation of diseases and disorders such as cancer. | 2015-10-08 |
20150283254 | POLYMERIC NANOPARTICLES - The presently-disclosed subject matter includes nanoparticles that comprise a plurality of assembled polymers. In some embodiments the polymers comprise a first block that includes hydrophilic monomers, the first block substantially forming an outer shell of the nanoparticle, and a second block that includes cationic monomers and hydrophobic monomers, the second block substantially forming a core of the nanoparticle. In some embodiments a polynucleotide is provided that is bound to the cationic monomers of the nanoparticle. The presently-disclosed subject matter also comprises methods for using the present nanoparticles to include RNAi in a cell as well as methods for making the present nanoparticles. | 2015-10-08 |
20150283255 | CD19 BINDING AGENTS AND USES THEREOF - This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease. | 2015-10-08 |
20150283256 | Poly(vinyl ester) Polymers for In Vivo Nucleic Acid Delivery - The present invention is directed membrane active poly(vinyl ester) polymers and compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cells in vivo. RNAi polynucleotides are conjugated to the poly(vinyl ester) polymers and the polymers are reversibly modified to enable in vivo targeted delivery. Membrane activity of the poly(vinyl ester) provides for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness. | 2015-10-08 |
20150283257 | CRYSTALLINE NALOXOL-PEG CONJUGATE - Naloxol-polyethylene glycol conjugates of the formula: | 2015-10-08 |
20150283258 | PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES - Conjugates of an antibody that binds to PSMA with PBD dimers. | 2015-10-08 |
20150283259 | DRUG-PROTEIN CONJUGATES - Specific conjugates containing maytansines and a binding protein or peptide, and processes for making them, are described. The conjugates use specific linker technology which gives advantages over known antibody-drug conjugates. | 2015-10-08 |
20150283260 | ANTIBODY-LIGHT FUSION PRODUCTS FOR CANCER THERAPEUTICS - Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases. | 2015-10-08 |
20150283261 | METHOD FOR SELECTIVE TARGETING AND ENTRY OF BACTERIAL TOXINS TO CELLS - The present invention provides methods and reagents for directing the selective targeting and entry of bacterial toxins to mammalian cells. Methods include the step of contacting a cell with a bacterial toxin or toxic bioactive fragment thereof associated with an antibody or ligand that is specific to a target on the cell, wherein the antibody or ligand selectively binds the target on the cell and the bacterial toxin or fragment thereof is internalized and enters the cell. The invention further encompasses compositions and kits to carry out the methods. | 2015-10-08 |
20150283262 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - Conjugates of an antibody that binds to CD19 with PBD dimers. | 2015-10-08 |
20150283263 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - Conjugates of an antibody that binds to CD25 with PBD dimers. | 2015-10-08 |
20150283264 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER - Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease. | 2015-10-08 |
20150283265 | METHODS TO REGULATE POLARIZATION AND ENHANCE FUNCTION OF CELLS - Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation. | 2015-10-08 |
20150283266 | CD25 PRE-SELECTIVE COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE - Recombinant vectors containing at least: a backbone comprising essential sequences for integration into a target cell genome; a nucleic acid encoding a CCR5 RNAi operatively linked to a a first expression control element that regulates expression of the nucleic acid encoding the RNAi of the CCR5; a nucleic acid encoding at least the extracellular domain of CD25 operatively linked to a second expression control element that regulates expression of the nucleic acid encoding at least the extracellular domain of CD25 are provided by this disclosure. In an alternative aspect, the vector also contains polynucleotides encoding TRIM5alpha and HIV TAR decoy sequences along with gene expression regulation elements such as promoters operatively linked to the polynucleotides. The vectors are combined with packaging plasmid and envelope plasmids and optionally conjugated to cell-specific targeting antibodies. Diagnostic and therapeutic methods for using the compositions are further provided herein. | 2015-10-08 |
20150283267 | Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof - The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor IX or factor VIII genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor IX or factor VIII genes are also disclosed. The present invention is particularly useful for applications using gene therapy, in particular for the treatment of hemophilia A and B. | 2015-10-08 |
20150283268 | SOLID ORAL COMPOSITION CONTAINING DYES FOR USE IN ENDOSCOPIC DIAGNOSIS - Herein described are solid oral compositions of dyes for use in diagnostic endoscopy, preferably colon endoscopy. | 2015-10-08 |
20150283269 | RECONSTITUTED HUMAN IMMUNE SYSTEM IN A PATIENT DERIVED XENOGRAFT MOUSE MODEL - The present teachings relate to methods of screening for a therapeutic agent, selecting a treatment and monitoring a treatment for a human disease or infection and methods for producing a mouse model for human disease or infection wherein the mouse has a functioning human immune system. The method includes administering a test substance to an immunocompromised NOD/SCID mouse with a reconstituted human immune system and is also engrafted with a substance containing a diseased or infectious cell derived from a human diseased or infected patient and a step of assessing improvement in the disease or infection of the mouse and/or to monitor a side effect of the test substance. | 2015-10-08 |
20150283270 | MODELING ANTI-LEUKEMIC THERAPY BY PATIENT DERIVED AML XENOGRAFTS WITH DISTINCT PHENOTYPES/GENOTYPES - The present teachings relate to methods of screening for a therapeutic agent for human acute myelogenous leukemia (AML) and methods for treating AML. The method includes administering a test substance to an immunocompromised NOD/SCID mouse engrafted with a substance containing a leukemic cell derived from a human AML patient and a step of assessing improvement in leukemia in the mouse and/or to monitor a side effect of the test substance. The method can further include monitoring a side effect of the test substance in the mouse. | 2015-10-08 |
20150283271 | METHOD FOR MIMICKING HUMAN CLINICAL TRIAL BY USING NON-HUMAN ANIMALS - The present invention provides a method for using non-human animals to mimick human clinical trial comprising: (a) obtaining cells or tissues from n human subjects suffered from a disease, wherein n>1; (b) establishing a control group and a treatment group, wherein i) the control group comprises i control non-human animals, wherein i≧n, wherein cells or tissue from each human subject are grafted to at least one control non-human animal; ii) the treatment group comprises j treatment non-human animals, wherein j≧n, wherein cells or tissue from each human subject are grafted to at least one treatment non-human animal; and iii) each control non-human animal or treatment non-human animal is grafted with cells or tissues from one human subject; (c) administering a first agent to the control group and administering a second agent to the treatment group, wherein the first agent is different from the second agent; (d) obtaining the end point of the control group and the treatment group; and (e) comparing the end point of the control group to the end point of the treatment group. | 2015-10-08 |
20150283272 | DUAL MODE GADOLINIUM NANOPARTICLE CONTRAST AGENTS - Provided herein are nanoparticle-based gadolinium (Gd) agents which may be used, e.g., in T1-weighted MR imaging (MRI). In various embodiments, dual-Gd liposomal agents are provided which contain both core-encapsulated Gd as well as surface-conjugated Gd. In various embodiments, these agents were observed to deliver a higher concentrations of Gd and result in substantial improvements in signal to noise ratios and contrast to noise ratios. Also provided are methods for in vivo imaging and/or treating diseases such as cancer or tumor in a subject. | 2015-10-08 |
20150283273 | Catalytic Radiofluorination - One aspect of the present invention relates to a method of preparing radiofluorinated substituted alkyl, cycloalkyl, aryl, and alkenyl compounds. In a preferred embodiment, potassium fluoride-18 is used. Another aspect of the invention relates to piperazine compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the piperazine compounds contain a quaternary amine. Another aspect of the invention relates to arylphosphonium compounds containing fluorine-18 that are useful as imaging agents. In certain embodiments, the phosphonium compound is a tetraaryl phosphonium salt. Another aspect of the present invention relates to a method of obtaining a positron emission image of a mammal, comprising the steps of administering to a mammal a compound of the invention, and acquiring a positron emission spectrum of the mammal. | 2015-10-08 |
20150283274 | RADIOISOTOPE TRITHIOL COMPLEXES - The present invention is directed to a series of stable radioisotope trithiol complexes that provide a simplified route for the direct complexation of radioisotopes present in low concentrations. In certain embodiments, the complex contains a linking domain configured to conjugate the radioisotope trithiol complex to a targeting vector. The invention is also directed to a novel method of linking the radioisotope to a trithiol compound to form the radioisotope trithiol complex. The inventive radioisotope trithiol complexes may be utilized for a variety of applications, including diagnostics and/or treatment in nuclear medicine. | 2015-10-08 |
20150283275 | Radiolabelled Antibody And Uses Thereof - The present disclosure describes a radioconjugate of an anti-CD38 antibody and a radionuclide, e.g., Bi | 2015-10-08 |
20150283276 | Method for Controlling Fungal Plant Pathogens Using a Combination of UV Radiation Followed by Antagonist Application and Dark Period - Strawberries are available year-around from production in the field or from controlled environments (e.g. high and low tunnel culture and greenhouse). Diversity of production conditions results in challenges in controlling diseases before, during, and after harvest. Fungicides, traditionally used to control diseases, have limitations. UV-C irradiation followed by a dark period was used to kill two major pathogens of strawberry, | 2015-10-08 |
20150283277 | Methods, Devices, and Systems for Treating Bacteria with Mechanical Stress Energy and Electromagnetic Energy - A portion of a treatment device for treating bacteria may be coupled with the bacteria through direct or indirect contact. Mechanical stress energy and electromagnetic energy are generated with the treatment device, and are transmitted from the treatment device to the bacteria during the coupling. The bacteria are treated with both the mechanical stress energy and the electromagnetic energy to produce a killing effect on the bacteria. A treatment device may include a mechanical stress energy emitting portion, an electromagnetic energy emitting portion, and a contacting portion for coupling into direct or indirect contact with the bacteria and transmitting mechanical stress energy to the bacteria during the coupling. The mechanical stress energy emitting portion and the electromagnetic energy emitting portion are operable to treat the bacteria with a combination of mechanical stress energy and electromagnetic energy to produce a killing effect on the bacteria. | 2015-10-08 |
20150283278 | ELECTROPORATION APPARATUSES AND THEIR METHOD OF USE - The device uses pulsed electric fields to prevent the growth of biofilm and the attachment of bacteria to targeted surfaces. The device sets up an electric field around or surrounding the surface itself. These pulsed electric fields disrupt biofilm formation and bacterial attachment to surfaces. The device is meant to prevent the formation of biofilm or attachment of bacteria to a surface as opposed to disinfecting the surface. | 2015-10-08 |
20150283279 | DEVICE FOR STERILIZATION BY ULTRAVIOLET RADIATION - In a known device for sterilization by ultraviolet radiation, a UV radiator ( | 2015-10-08 |
20150283280 | WAX WARMER - A wax warmer includes a reservoir module for receiving a wax melt, a heater module, and a base module. The heater module includes a heating element. The reservoir module, the heater module, and the base module are removable from one another in the normal use of the wax warmer and may be replaced by a second reservoir module, a second heater module, or a second base module, respectively. | 2015-10-08 |
20150283281 | LIQUID PRESENCE DETECTING DEVICE FUNCTIONING ALSO AS POWER SUPPLY, AND AIR IMPROVING DEVICE HAVING THE SAME - A liquid presence detecting device that has a simple and compact configuration, and which is high in efficiency, and an air improving device including the detecting device. The liquid presence detecting device includes a magnesium-air battery, and an electrical load. When liquid exists in a detection point, the magnesium-air battery operates (generates electricity), and, when liquid does not exist in the detection point, the operation of the magnesium-air battery stops. Therefore, the liquid presence detecting device detects the presence of liquid, and functions also as a power supply. The air improving device includes the liquid presence detecting device functioning also as a power supply, a device body, and an air improver which is detachably attached into the device body. | 2015-10-08 |
20150283282 | OLFACTORY DISPLAY AND FRAGRANCE SOURCE CARTRIDGE USED THEREIN - An olfactory display | 2015-10-08 |
20150283283 | Plasma Injection Air Filtration And Disinfection System - Disclosed herein is a plasma reactor insert assembly having in one example an outer casing comprising; a fluid inlet; a fluid outlet; an electric power input; and electric power connector; a transformer bracket coupled to the outer casing; at least one step-up transformer attached to the transformer bracket. The insert in electric communication with the electric power connector; a plurality of substantially parallel dielectric tubes in electric communication with the transformer; at least one grounded plate positioned between each dielectric tube with a fluid gap there between, and; wherein there is no fluid path between the fluid inlet and the fluid outlet except by passing between one of the dielectric tubes and one of the grounded plate. In one form, each grounded plate is v-shaped or arcuate v-shaped in cross-section. A method for disinfecting or sanitizing using the plasma reactor is also described. | 2015-10-08 |
20150283284 | SUPERABSORBENT POLYMER HAVING FAST ABSORPTION - The present invention relates to a particulate superabsorbent polymer composition having fast absorption and a method of making the particulate superabsorbent polymer comprising a monomer solution comprising a foaming agent and a mixture of a lipophile surfactant and a polyethoxylated hydrophilic surfactant wherein the particulate superabsorbent polymer composition has a mean particle size distribution of from 300 to 500 μm and a vortex time of 30 to 60 seconds. The present invention further includes particulate superabsorbent polymer compositions surface treated with other components. The present invention further includes absorbent cores and articles including the particulate superabsorbent polymer compositions. | 2015-10-08 |
20150283285 | MULTI-LAYER ARTICLES - Multilayer articles having an absorbent nonwoven layer and a barrier layer are described, including those having a surfactant-treated, aliphatic polyester, nonwoven absorbent layer and a barrier layer. Multilayer articles including a tie layer used to enhance the bond between the hydrophilic absorbent layer and the barrier layer are also described. Methods of making and using such articles are also described. | 2015-10-08 |
20150283286 | NOVEL HEMOSTATIC COMPOSITIONS AND DRESSINGS FOR BLEEDING - The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile ( | 2015-10-08 |
20150283287 | METHODS AND COMPOSITIONS FOR WOUND HEALING - The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polyelectrolytes to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound. | 2015-10-08 |
20150283288 | SOLID DRESSING FOR TREATING WOUNDED TISSUE - Disclosed are solid dressings for treated wounded tissue in mammalian patients, such as a human, comprising a haemostatic layer consisting essentially of a fibrinogen component and a fibrinogen activator, wherein the haemostatic layer(s) is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator. Also disclosed are methods for treating wounded tissue using these dressings and frozen compositions useful for preparing the haemostatic layer(s) of these dressings. | 2015-10-08 |
20150283289 | NONWOVEN FABRIC AND ABSORBENT ARTICLE - A nonwoven fabric for a top sheet of an absorbent article has a lengthwise direction and a width direction. The nonwoven fabric has a plurality of units in the width direction including first, second, third and fourth areas extending in the lengthwise direction. The second and fourth areas have a higher content by percentage of fibers that are oriented in the lengthwise direction than the third area. The first area has a higher content by percentage of fibers that are oriented in the width direction than the third area. The second, third area, and fourth area respectively include a predetermined blood lubricity-imparting agent, the blood lubricity-imparting agent, and the blood lubricity-imparting agent. The basis weights of the blood-lubricity imparting agent in the second area and in the fourth area are higher than that of the blood lubricity-imparting agent in the third area. | 2015-10-08 |
20150283290 | STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES - Sterilized wound healing compositions comprise stabilized cyanoacrylate monomers homogenously mixed together with a naphthoquinone 2,3-oxide, including vitamin K oxides. The compositions are sterilized by irradiation, and the sterilized compositions are shelf stable such that their viscosity does not substantially increase following at least two years of shelf storage. The compositions may be used for closure of open wounds, and the compositions enhance the rate of wound healing relative to wounds not closed with the compositions. | 2015-10-08 |
20150283291 | Fosfomycin preparation, a method for producing the preparation, and a polymethylmethacrylate bone cement powder containing the preparation - The invention relates to a fosfomycin preparation that comprises a) a calcium salt of fosfomycin and b) at least one sugar alcohol having a melting point above 70° C., whereby the weight ratio of sugar alcohol to calcium salt of fosfomycin is at least 0.8. Moreover, the invention proposes a method for producing the fosfomycin preparation and a polymethylmethacrylate bone cement powder that contains the fosfomycin preparation. | 2015-10-08 |
20150283292 | COMPOSITIONS AND METHODS FOR TREATING BONE DEFECTS - A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided. | 2015-10-08 |
20150283293 | BIOADHESIVE FOR TISSUE REPAIR - The invention provides a bioadhesive composition comprising a polysaccharide and an energy converter, wherein the energy converter is activated by non-UV light. The composition may be prepared by dissolving the polysaccharide and the energy converter in an aqueous acidic solution. The composition, in the form of a film or a gel, may be used for repairing a discontinuity in an area of tissue or for joining tissue. | 2015-10-08 |
20150283294 | Mesoporous calcium silicate compositions and Methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents - Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid. A hydrated silica gel layer having abundant Si—OH functional groups can be formed on the surface of wollastonite after acid modification. Bruhauer-Emmett-Teller (BET) surface area increased significantly due to acid modification and, in one arrangement, reached over 350 m | 2015-10-08 |
20150283295 | POROUS COATING FOR SURGICAL ORTHOPEDIC IMPLANTS - A surgical implant component comprising an implant component body manufactured from a Co-based substrate alloy comprising Co, Cr, Mo, Si, and C, and a coating on a bone-ingrowth surface of the component body manufactured from a Co-based coating alloy comprising Co, Cr, Mo, Si, C and B. The coating is a network of fused particles of the Co-based coating alloy with spherical particles, irregular aspherical particles, and between about 35 and about 70 volume % porosity. A method of manufacturing the foregoing surgical implant component. | 2015-10-08 |
20150283296 | BIOACTIVE GLASS WITH ETHYLENE OXIDE PROPLYENE OXIDE BLOCK COPOLYMERS - Bone repair composition including a bone repair material suspended in a mixture of non-random poly(oxyalkylene) block copolymer and water exhibiting reverse phase behavior when the temperature increases from room temperature to body temperature. There are many materials used today for the repair and regeneration of bone defects. Bone is a composite of collagen, cells, calcium hydroxyapatite crystals, and small quantities of other proteins of organic molecules that has unique properties of high strength, rigidity, and ability to adapt to varying loads. | 2015-10-08 |
20150283297 | Multilayer preform obtained by electro-spinning, method for producing a preform as well as use thereof - The invention relates a multilayer preform obtained by electro-spinning, which preform is suitable as a scaffold for a prosthesis, which preform comprises layers of different diameter microfibers. The present invention also relates to a method of producing said preform. The present invention also relates to the use of the present preform as a substrate for growing human or animal tissue thereon. The present invention furthermore relates to a method for growing human or animal tissue on a substrate, wherein the present preform is used as the substrate. | 2015-10-08 |
20150283298 | SILK-BASED FABRICATION TECHNIQUES TO PREPARE HIGH STRENGTH CALCIUM PHOSPHATE CERAMIC SCAFFOLDS - The disclosure provides ceramic materials comprising calcium phosphate material and silk and processes and methods for preparing and uses thereof. | 2015-10-08 |
20150283299 | METHOD FOR PRODUCING A COLLAGEN MEMBRANE AND USES THEREOF - The present invention relates to a method of producing a collagen membrane that has particular mechanical properties. In particular, the present invention relates to a method A of producing a collagen membrane comprising the steps of (i) isolating a collagen-containing tissue and incubating same in an ethanol solution; (ii) incubating the collagen-containing tissue from step (i) in a first solution comprising an inorganic salt and an anionic surfactant in order to denature non-collagenous proteins contained therein; (iii) incubating the collagen-containing tissue produced in step (ii) in a second solution comprising an inorganic acid until the collagen in said material is denatured; and (iv) incubating the collagen-containing tissue produced in step (iii) in a third solution comprising an inorganic acid with simultaneous mechanical stimulation for sufficient time to enable the collagen bundles in said collagen-containing tissue to align; wherein the mechanical stimulation comprises applying tension cyclically to the collagen-containing tissue. | 2015-10-08 |
20150283300 | BIOACTIVE GLASSES WITH SURFACE IMMOBILIZED PEPTIDES AND USES THEREOF - The invention relates to bioactive glass compositions that include bioactive glass with surface immobilized peptides and methods and uses thereof. | 2015-10-08 |
20150283301 | METHOD FOR GRAFTING POLYMERS ON METALLIC SUBSTRATES - A method of conferring modified properties, e.g. modified physical and/or biochemical properties, to a metallic substrate surface, including at least two steps being (i) a first step including at least exposing the substrate surface to a hetero-bifunctional anchoring molecule carrying at least a silane group and at least a A | 2015-10-08 |
20150283302 | Natural Tissue Scaffolds as Tissue Fillers - Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers. | 2015-10-08 |
20150283303 | METHODS OF TRANSPLANTING CHONDROCYTES - Provided are tri-component matrices having collagen, hyaluronan, and chondroitin sulfate. Also provided are processes for producing a tri-component matrix. Additionally, provided are processes for providing cells capable of producing cartilage to a bone or cartilage defects. | 2015-10-08 |
20150283304 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS - The invention relates to oligofluorinated coatings and their use in drag delivery. The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue. This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface. | 2015-10-08 |
20150283305 | METHODS OF MAKING COLLAGEN FIBER MEDICAL CONSTRUCTS AND RELATED MEDICAL CONSTRUCTS, INCLUDING NERVE GUIDES AND PATCHES - The disclosure describes methods of winding collagen fiber to make medical constructs and related collagen fiber tube and patch devices. | 2015-10-08 |
20150283306 | EMBOLIC DEVICES - Described herein are apparatus, compositions, systems and methods for occluding vascular structures and vascular malformations with radiopaque hydrogel filaments. The filaments can contain no support members and can be CT and MR compatible. Methods of forming such filaments are also disclosed. | 2015-10-08 |
20150283307 | THERMAL CHEMICAL VAPOR DEPOSITION COATED ARTICLE AND PROCESS - A coated article is disclosed. The article includes a coating formed by thermal decomposition, oxidation then functionalization. The article is configured for a marine environment, the marine environment including fouling features. The coating is resistant to the fouling features. Additionally or alternatively, the article is a medical device configured for a protein-containing environment, the protein-containing environment including protein adsorption features. The coating is resistant to the protein adsorption features. | 2015-10-08 |
20150283308 | ENDOLUMINAL DEVICE AND METHOD OF IMPLANTING SAME - Implanting an endoluminal device in a patient includes advancing the device to a treatment location in a patient, and deploying the device such that it contacts body tissue forming an inner wall of a body lumen. The implantation further includes inciting an immune reaction in the body tissue via a sclerosant in a coating of the device, and promoting ingrowth of new body tissue triggered by the sclerosant about the device via a bioremodelable material in the coating so as to anchor the device at the treatment location. | 2015-10-08 |
20150283309 | ASPIRATION MONITORING SYSTEM AND METHOD - In one embodiment, system for real time monitoring of catheter aspiration includes a housing having a first port adapted for connection to a vacuum source and a second port adapted for connection with an aspiration catheter, a pressure sensor in fluid communication with an interior of the housing, a measurement device coupled to the pressure sensor and configured for measuring deviations in fluid pressure, and a communication device coupled to the measurement device and configured to generate an alert signal when a deviation in fluid pressure measured by the measurement device exceeds a pre-set threshold. In another embodiment, the system for real time monitoring of catheter aspiration further includes a vacuum source for connection to the first port and an aspiration catheter having an aspiration lumen for connection to the second port. | 2015-10-08 |
20150283310 | SURGICAL SWAB WASHING METHOD AND APPARATUS - Automated methods and apparatus for washing surgical swabs to extract viable red blood cells from said swabs. One method comprises contacting at least one swab retaining viable red blood cells with saline-based wash solution in a receptacle under sterile conditions; and effecting the automated compression and/or agitation of the receptacle containing the swab(s), saline-based wash solution and red blood cells to facilitate extraction of viable red blood cells from the swabs into the saline-based wash solution. Another method comprises providing at least one swab retaining viable red blood cells in a receptacle; providing saline-based wash solution in said receptacle so that it contacts said swab(s) such that viable red blood cells are extracted from the swab(s) into the saline-based wash solution; effecting automated compression and/or agitation of the receptacle containing the swab(s), saline-based wash solution and red blood cells to facilitate extraction of viable red blood cells from the swab(s) into the saline-based wash solution; and pumping saline-based wash solution containing viable red blood cells extracted from the swab(s) to a reservoir. | 2015-10-08 |
20150283311 | METHOD, APPARATUS, AND SYSTEM FOR EXPRESSION OF HUMAN BREAST MILK - Systems, methods, and devices for milk expression are provided. In one aspect, a system includes an expression apparatus having an interface configured to engage a breast and an actuation assembly operably coupled to the interface. Actuation of the actuation assembly causes the interface to apply vacuum pressure against the breast to express milk from the breast. The system also includes a computing device configured to communicate with the expression apparatus via a data connection. | 2015-10-08 |
20150283312 | APPARATUS AND METHOD FOR MODIFYING PRESSURE-FLOW CHARACTERISTICS OF A PUMP - Blood pump systems including a continuous flow blood pump and methods for controlling a continuous flow blood pump operate the blood pump to simulate target pressure-flow characteristics that are different from native pressure-flow characteristics of the blood pump. A method for controlling a continuous flow blood pump driven by a motor includes operating the motor at a first rotational rate. A first flow rate of the continuous flow blood pump driven at the first rotational rate is measured and/or estimated. The first flow rate is used to determine a second rotational rate based on target pump characteristic data corresponding to target pressure-flow characteristics for the continuous flow blood pump different from pressure-flow characteristics of the continuous flow blood pump when driven by the motor at a constant rotational speed. The second rotational rate is different from the first rotational rate. The motor is then operated at the second rotational rate. | 2015-10-08 |
20150283313 | COIL FOR INDUCTIVE TRANSCUTANEOUS ENERGY AND/OR DATA TRANSFER FOR ACTIVE MEDICAL IMPLANTS - The invention relates to a coil for inductive transcutaneous transfer of electrical power for the power supply of active medical implants, where coil windings are designed with a conductor and run around a centre in spiral shape. | 2015-10-08 |
20150283314 | Dialysate supply unit and blood dialyzing apparatus having the same - Provided is a dialysate supply unit and a blood dialyzing apparatus including the dialysate supply unit for supplying dialysate of a dialysate tank to a hemodialyzer and collecting dialysate passing through the hemodialyzer in an effluent tank. The dialysate supply unit includes a dialysate pump, an effluent pump, a first flow-blocking valve, a second flow-blocking valve, and a flow-blocking valve driver. The dialysate pump connects the dialysate tank and the hemodialyzer and the effluent pump connects the hemodialyzer and the effluent tank. The first flow-blocking valve alternately blocks a dialysate outflow tube connecting the hemodialyzer and the dialysate pump and an effluent inflow tube connecting the hemodialyzer and the effluent pump. The second flow-blocking valve alternately blocks a dialysate inflow tube connecting the dialysate pump and the dialysate tank and an effluent outflow tube connecting the effluent pump and the effluent tank. The flow-blocking valve driver drives the flow-blocking valve. | 2015-10-08 |
20150283315 | Blood purifying filter and blood purifying apparatus having the same - Provided are a blood purifying filter and a blood purifying apparatus including the same. The blood purifying filter includes a plasma separation filter, a hemodialysis filter, a housing, and a plasma outlet. The plasma separation filter separates plasma from blood. The hemodialysis filter removes toxins and waste products from blood. The housing provides installation spaces for the plasma separation filter and the hemodialysis filter and defines a plasma flow section outside the plasma separation filter and the hemodialysis filter. The plasma outlet is provided at one side of the housing to allow plasma passing the plasma flow section to be discharged out of the blood purifying filter. | 2015-10-08 |
20150283316 | MICRO-PILLAR ARRAY METHOD AND APPARATUS - A micro-pillar array assembly including an inlet for receiving a biological fluid including components of the biological fluid, an outlet, and a cavity formed between the inlet and the outlet, the cavity further comprising a plurality of micro-pillar arrays positioned to remove cellular components of the biological fluid to produce a resulting fluid. Another assembly, a method and a system are also disclosed. | 2015-10-08 |
20150283317 | APPARATUS FOR NITRIC OXIDE DELIVERY TO A PATIENT AND METHODS OF USING SAME - Nitric oxide delivery devices comprise a chamber ( | 2015-10-08 |
20150283318 | Methods to detect and treat diseases - The current invention discloses methods to treat disease caused by virus infection, bacterial infection, parasites infection, autoimmune disease, disease caused by production of unwanted antibodies, sepsis as well as methods to treat cancer and methods for virus infection detection using blood purification method. The current invention provides a method to treat pathogen infection by inactivating the pathogens in the blood. During the treatment, blood is withdrawn from a patient and is separated into its plasma and cellular components. The plasma portion is treated with physical means such as UV radiation to inactivate the pathogens inside and then is returned to the patient. The current invention also provide a method to treat cancer especially to prevent tumor metastasis and tumor recurrence by removing and/or inactivating (e.g. killing) the circulating tumor cells (CTC) in the blood after removing the tumor or treating the tumor with therapeutical means. | 2015-10-08 |
20150283319 | AUTOMATIC CONTRAST-AGENT INJECTION DETECTION - Apparatus and methods are described, for use with a contrast agent that is injected into a blood vessel of a subject. The apparatus and methods include acquiring a plurality of image frames of the subject's blood vessel, acquisition of the image frames commencing prior to injection of the contrast agent into the blood vessel. Using at least one processor, one of the image frames is automatically identified as being an image frame in which an angiographic sequence commenced, by determining that, in the image frame, there is a change in a characteristic of the image frame relative to at least one image frame acquired prior to the image frame that is indicative of a presence of contrast agent within the image. An output is generated at least partially in response thereto. Other applications are also described. | 2015-10-08 |
20150283320 | MEDICAL TREATMENT METHOD, MEDICAL TREATMENT APPARATUS, AND MEDICAL TREATMENT SYSTEM FOR BLOODSTREAM DISORDER - Occlusion of a blood vessel is improved by a medical treatment system including a ejection device that includes an insertion section insertable into a tissue of an animal and is capable of ejecting first liquid as a pulsating flow from a distal end of the insertion section and a control apparatus configured to bring the distal end of the insertion section close to a blood vessel in the tissue, which is a medical treatment target, and eject the first liquid as the pulsating flow from the distal end of the insertion section in a state in which second liquid is interposed in a region covering the blood vessel. | 2015-10-08 |
20150283321 | PRIMING DETECTION SYSTEM AND METHOD OF USING THE SAME - An infusion system having a priming detection system to indicate that a component of the system, for example a cannula or needle, is primed with a fluid to be delivered into an individual's body. The infusion system utilizes a reactive element that reacts with the fluid or at least one component of the fluid to be delivered, to produce a color change or a colored complex. The reactive element can be deposited, coated or otherwise incorporated in any component of the infusion system that would benefit from a visible indication of a primed fluid, including, but not limited to a tubing, infusion set, cannula, needle and/or guard element at least partially covering or surrounding a cannula or needle. The visual indication improves the user experience during the priming and filling of the system by providing a clear color change confirmation upon priming completion and prior to insertion into the body. | 2015-10-08 |
20150283322 | METHODS AND SYSTEMS FOR FILLING IV BAGS WITH THERAPEUTIC FLUID - A portable electronic fluid dispensing system can provide pre-filled, pre-primed IV bag assemblies comprising therapeutic fluids. The same fluid line and connector in the IV bag assembly can be used to fill the IV bag as is used to withdraw fluid from the IV bag and infuse such fluid into the patient. The connection points along the IV assembly, such as the connection between the IV bag and a drip chamber, or between an IV bag and tubing, or between a drip chamber and tubing, or between tubing and a closeable, resealable connector, can each be resistant to disconnection by a user. The healthcare practitioner at the patient care site is not required to attach any of these components to each other, and the healthcare practitioner at the patient care site is not required to introduce a spike into a spike port on the IV bag. | 2015-10-08 |
20150283323 | AUTOMATIC DRUG DELIVERY DEVICES - The invention provides in one aspect a drug delivery device comprising a drug container ( | 2015-10-08 |